Vital Therapies currently has a Zacks Rank #3 (Hold). Vital Therapies Inc (NASDAQ:VTL) weekly performance is -0.91. On last trading day company shares ended up $27.25. Analysts mean target price for the company is $21.00. Vital Therapies Inc (NASDAQ:VTL) distance from 50-day simple moving average is 52.00%.
On May 13, 2014 ImmuCell Corporation (NASDAQ:ICCC) , a growing animal health company that is developing, manufacturing and selling products that improve animal health and productivity in the dairy and beef industries, announced financial results for its first quarter ended March 31, 2014. ImmuCell Corporation (NASDAQ:ICCC) shares advanced 9.15% in last trading session and ended the day on $4.65. ICCC Gross Margin is -4.80% and its return on assets is 0.90%. ImmuCell Corporation (NASDAQ:ICCC) quarterly performance is 3.10%.
Ardelyx, Inc. (Nasdaq: ARDX), a clinical-stage biopharmaceutical company focused on cardio-renal, GI and metabolic diseases, announced the closing of its initial public offering of 4,928,900 shares of common stock at an initial public offering price of $14.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to 642,900 additional shares of common stock. All of the shares of common stock were offered by Ardelyx. The Company’s shares began trading on The NASDAQ Global Market under the ticker symbol “ARDX” on June 19, 2014. Ardelyx estimates net proceeds from the offering to be approximately $60.8 million, after deducting underwriting discounts and commissions and estimated offering expenses. Ardelyx Inc (NASDAQ:ARDX) shares moved up 9.58% in last trading session and was closed at $19.44, while trading in range of $17.86-$19.49. Ardelyx Inc (NASDAQ:ARDX) year to date performance is 37.77%.
Applied Genetic Technologies (Nasdaq: AGTC) announced that it has appointed David R. Guyer, MD, and Ivana Magovcevic-Liebisch, PhD, JD, to the company’s Board of Directors. Applied Genetic Technologies Corp (NASDAQ:AGTC) ended the last trading day at $24.16. Company weekly volatility is calculated as 12.16% and price to cash ratio as 13.88. Applied Genetic Technologies Corp (NASDAQ:AGTC) showed a negative weekly performance of -21.17%.
China Biologic Products, Inc. (NASDAQ: CBPO, “China Biologic” or the “Company”), a leading plasma-based biopharmaceutical company in China , announced the pricing of a follow-on offering of 1,550,000 shares of common stock at a public offering price of $38.00 per share. The Company will be offering 800,000 shares and a selling stockholder will be offering 750,000 shares of common stock. In addition, the underwriters have a 30-day option to purchase up to 120,000 additional shares of common stock from the Company and 112,500 additional shares of common stock from the selling stockholder. China Biologic Products Inc (NASDAQ:CBPO) net profit margin is 35.10% and weekly performance is 17.31%. On last trading day company shares ended up $47.84. Analysts mean target price for the company is $51.00. China Biologic Products Inc (NASDAQ:CBPO) distance from 50-day simple moving average is 13.45%.